Breaking News Instant updates and real-time market news.

ADRO

Aduro Biotech

$10.90

0.1 (0.93%)

, CRY

CryoLife

$21.65

-0.2 (-0.92%)

08:12
09/26/17
09/26
08:12
09/26/17
08:12

Ladenburg to hold a conference

2017 Healthcare Conference is being held in New York on September 26.

ADRO

Aduro Biotech

$10.90

0.1 (0.93%)

CRY

CryoLife

$21.65

-0.2 (-0.92%)

BCRX

BioCryst

$5.26

0.02 (0.38%)

VIVE

Viveve

$5.77

-0.22 (-3.67%)

MZOR

Mazor Robotics

$47.43

-1.28 (-2.63%)

SGYP

Synergy Pharmaceuticals

$2.61

0.02 (0.77%)

PSDV

pSivida

LPCN

Lipocine

ARDM

Aradigm

$3.36

0.83 (32.81%)

ARNA

Arena Pharmaceuticals

$25.75

0.66 (2.63%)

BDSI

BioDelivery Sciences

AVXL

Anavex

$4.01

-0.12 (-2.91%)

OFIX

Orthofix

$47.66

-0.19 (-0.40%)

VNRX

VolitionRx

$2.88

-0.1 (-3.36%)

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 27

    Sep

  • 28

    Sep

  • 16

    Nov

  • 24

    Jan

ADRO Aduro Biotech
$10.90

0.1 (0.93%)

03/07/17
03/07/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Aduro Biotech (ADRO) reinitiated with a Buy at Roth Capital. 2 Foundation Building Materials (FBM) initiated with a Buy at SunTrust and Citi, an Outperform at Raymond James and RBC Capital, and an Overweight at Barclays. 3. Coca-Cola European Partners (CCE) initiated with a Buy at Argus. 4. Agrium (AGU) initiated with an Outperform at Bernstein. 5. Teleflex (TFX) initiated with a Buy at Needham. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/01/17
RODM
05/01/17
INITIATION
Target $18
RODM
Buy
Aduro Biotech initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Joseph Pantginis started Aduro Biotech with an Outperform rating and $18 price target. The company is building a broad portfolio of immuno-oncology assets, the analyst contends.
07/18/17
COWN
07/18/17
INITIATION
COWN
Outperform
Aduro Biotech initiated with an Outperform at Cowen
Cowen analyst Chris Shibutani initiated Aduro Biotech with an Outperform saying its three distinct immune-oncology platforms strongly position them as an emerging leader in oncology, and its $2.4B worth deals with pharma provides validation. He believes Auduro's proprietary platforms remain underappreciated by investors for their ability to target all the nodes of the cancer-immunity cycle. Shibutani said the future of immune-oncology is all about combo therapies and Aduro's extensive pipeline positions them to streamline clinical development of a wide range of interesting combinations.
03/07/17
ROTH
03/07/17
INITIATION
Target $17
ROTH
Buy
Aduro Biotech reinitiated with a Buy at Roth Capital
Roth Capital analyst Mark Breidenbach reinitiated Aduro Biotech with a Buy rating and $17 price target based on a sum-of-parts, probability-adjusted NPV analysis. The analyst believes the company has assembled an "impressive collection of immuno-oncology assets" and has demonstrated encouraging proof-of-concept clinical results in mesothelioma.
CRY CryoLife
$21.65

-0.2 (-0.92%)

02/17/17
LTCO
02/17/17
UPGRADE
Target $20
LTCO
Buy
CryoLife upgraded to Buy from Neutral at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen upgraded CryoLife to Buy following the company's Q4 results. On-X aortic and mitral prosthetic valves are currently very well positioned for growth, the analyst contends. He raised his price target for the shares to $20 from $15.
07/26/17
ADAM
07/26/17
NO CHANGE
Target $25
ADAM
Buy
CryoLife foundation suggests opportunity for growth, says Canaccord
Canaccord analyst Jason Mills recommended investors build positions in CryoLife on the heels of solid Q2 results. The analyst noted its better than expected top and bottom line results and said its strong foundation portends a huge opportunity for growth via both its internal pipeline and M&A. Mills reiterated his Buy rating and raised his price target to $25 from $23.50 on CryoLife shares.
BCRX BioCryst
$5.26

0.02 (0.38%)

09/06/17
JEFF
09/06/17
UPGRADE
JEFF
Buy
BioCryst upgraded to Buy from Hold at Jefferies
09/14/17
RBCM
09/14/17
INITIATION
Target $6
RBCM
Sector Perform
BioCryst initiated with a Sector Perform at RBC Capital
RBC Capital analyst Brian Abrahams started BioCryst Pharmaceuticals with a Sector Perform rating and $6 price target.
09/06/17
JEFF
09/06/17
UPGRADE
Target $7
JEFF
Buy
BioCryst upgraded to Buy with $7 target at Jefferies
Jefferies analyst Maury Raycroft upgraded BioCryst Pharmaceuticals to Buy from Hold and raised his price target for the shares to $7 from $5. The final APeX-1 data readout gives BCX7353 a better chance of success in a Phase III trial, Raycroft tells investors in a research note. Further, the analyst sees increased potential for eventual approval given the need for an oral option. Raycroft views BioCryst shares as undervalued. JPMorgan last night also upgraded BioCryst.
09/06/17
JPMS
09/06/17
UPGRADE
Target $9
JPMS
Overweight
BioCryst upgraded to Overweight with $9 target at JPMorgan
JPMorgan analyst Jessica Fye after the close last night upgraded BioCryst Pharmaceuticals to Overweight from Neutral and raised her price target for the shares to $9 from $6. The shares closed yesterday down 7c to $4.93. The analyst views the company's final results from the APeX-1 trial for BCX7353 in the prevention of hereditary angioedema attacks as encouraging. The results confirm an effective HAE attack prevention agent and one that justifies a valuation greater than the company's current $400M market capitalization, Fye tells investors in a research note.
VIVE Viveve
$5.77

-0.22 (-3.67%)

05/03/17
05/03/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Bob Evans (BOBE) initiated with an Outperform at William Blair. 2. C&J Energy Services (CJ) initiated with a Buy at Deutsche Bank. 3. Ironwood (IRWD) initiated with an Outperform at Wells Fargo. 4. Viveve (VIVE) initiated with an Outperform at Cowen. 5. LCI Industries (LCII) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/21/17
COWN
08/21/17
NO CHANGE
Target $11
COWN
Outperform
Viveve weakness a buying opportunity, says Cowen
Cowen analyst Joshua Jennings noted Viveve shares are down more than 50% from its highs reached in April as the stock has declined further following Q2 results. The analyst believes the pullback is a buying opportunity, as he expects continued U.S. momentum, improved performance outside of the U.S. and predicts the receipt of FDA approval for the VIVEVE ll IDE. Jennings reiterated his Outperform rating and $11 price target on Viveve shares.
05/24/17
RAJA
05/24/17
INITIATION
Target $10
RAJA
Outperform
Viveve initiated with an Outperform at Raymond James
Raymond James analyst Jayson Bedford initiated Viveve with an Outperform and a $10 price target saying its Geneveve System uses radiofrequency energy to treat vaginal laxity with a non-invasive, 30-minute procedure. The company received FDA clearance in Q4 2016for its Geneveve system, and the analyst expects revenue to double in 2017 and grow approximately 70% in 2018 and said the total US market is approximately $1.2B+.
05/03/17
COWN
05/03/17
INITIATION
Target $11
COWN
Outperform
Viveve initiated with an Outperform at Cowen
Cowen analyst Joshua Jennings initiated Viveve with an Outperform and an $11 price target telling investors shares are undervalued. The analyst said Viveve is within a few months of starting its VIVEVE II clinical study, and if successful, should yield a major commercial advantage in the form of an FDA label to improve female sexual function.
MZOR Mazor Robotics
$47.43

-1.28 (-2.63%)

05/12/17
JMPS
05/12/17
DOWNGRADE
JMPS
Market Perform
Mazor Robotics downgraded on valuation at JMP Securities
As noted earlier, JMP Securities downgraded Mazor to Market Perform from Outperform. Analyst David Turkaly downgraded the stock based on valuation.
08/30/17
LTCO
08/30/17
NO CHANGE
Target $54
LTCO
Buy
Mazor Robotics price target raised to $54 from $46 at Ladenburg
Ladenburg analyst Jeffrey Cohen noted that Mazor Robotics (MZOR) announced that it has entered the next phase of its strategic partnership with Medtronic (MDT) earlier than planned. He raised his price target on Mazor shares to $54 from $46, citing his valuation of the company's spine platform as well as his view of the value of its other market opportunities, and he keeps a Buy rating on the shares.
05/24/17
NEED
05/24/17
NO CHANGE
NEED
Hold
Medtronic unlikely to buy Mazor Robotics in near-term, says Needham
Needham analyst Mike Matson attributes some of the year-to-date advance in shares of Mazor Robotics (MZOR) to speculation that Medtronic (MDT) will acquire the company, though he sees that as unlikely in the near-term. Mazor shares are now trading "well above" the multiple that Stryker (SYK) paid to acquire Mako, noted Matson, who thinks its possible that Medtronic could eventually buy Mazor but only if the multiple declines via either a lower stock price or higher revenue. He keeps a Hold rating on Mazor shares.
05/12/17
05/12/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Sell from Hold at Deutsche Bank with analyst John Inch saying the stock is overvalued given "weak earnings quality" and the "wide gap between non-cash and cash earnings." 2. Electronic Arts (EA) was downgraded to Neutral from Long-Term Buy at Hilliard Lyons and to Sell from Hold at Deutsche Bank. 3. Uni-Pixel (UNXL) downgraded to Neutral from Buy at Roth Capital with analyst Brian Alger saying while he sees abundant industry demand and interest for the company's products, he sees Uni-Pixel's future as somewhat binary and dependent upon strategic partnerships being executed relatively quickly. Alger also lowered his price target on the shares to 45c from $2. 4. Akari Therapeutics (AKTX) downgraded to Market Perform from Outperform at William Blair with analyst Tim Lugo citing the company's announcement that it placed its Chief Executive Officer on administrative leave as it reviews any involvement with the Edison Report. 5. Mazor Robotics (MZOR) downgraded to Market Perform from Outperform at JMP Securities with analyst David Turkaly citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SGYP Synergy Pharmaceuticals
$2.61

0.02 (0.77%)

06/02/17
06/02/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Synergy Pharmaceuticals (SGYP) initiated with an Overweight at Cantor. 2. Fastenal (FAST) was initiated with an Overweight at Stephens and a Neutral at JPMorgan. 3. Ericsson (ERIC) was reinstated with a Buy at BofA/Merrill while Nokia (NOK) was reinstated with a Neutral. 4. John Bean Technologies (JBT) initiated with a Neutral at JPMorgan. 5. Biocept (BIOC) initiated with a Buy at Chardan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/08/17
OPCO
09/08/17
NO CHANGE
Target $6
OPCO
Outperform
Oppenheimer still sees value in shares of Synergy Pharmaceuticals
Oppenheimer analyst Derek Archila says that while there wasn't much new on yesterday's business update call, he remains encouraged by the ongoing Trulance launch. He believes the recent financing gives Synergy Pharmaceuticals "decent runway" to see what it can achieve with Trulance over the next 12-18 months. The analyst notes, however, that in the case of a takeout, Synergy would likely be required to pre-pay any outstanding loan amount at a 40% premium, which he believes could deter a potential buyer. The analyst still sees value in Synergy shares and keeps an Outperform rating on the name, despite reducing his price target to $6 from $9. Archila admits that he's not completely certain the company can reach cash flow breakeven by 2019 as management suggests.
09/13/17
SBSH
09/13/17
NO CHANGE
Target $2.5
SBSH
Sell
Synergy Pharmaceuticals price target lowered to $2.50 from $3.20 at Citi
Citi analyst Liav Abraham cut her price target for Synergy Pharmaceuticals to $2.50 and reiterates a Sell rating on the shares. The intellectual property on the company's lead compound, Trulance, expires in 2032, which, in the absence of life-cycle management programs, implies "minimal terminal value of the company over the longer term," Abraham tells investors in a research note. The analyst says that even with the stock's underperformance this year, she still struggles to become more constructive on the name.
09/25/17
HCWC
09/25/17
NO CHANGE
Target $8
HCWC
Buy
Synergy Pharmaceuticals price target lowered to $8 from $15 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered his price target for Synergy Pharmaceuticals to $8 saying the ramp for Trulance is likely to be "meaningfully slower" than he originally anticipated. Further, management have indicated that direct-to-consumer advertising is likely to be part of the promotional strategy, which could increase total marketing expenses significantly, Selvaraju tells investors in a research note. He lowered his 2017 Trulance sales estimate to $17.5M from $27.7M and 2018 estimate to $85.4M from $172.5M. The analyst also removed all contributions from Synergy's pipeline from his valuation assessment, based on the assumption that the company is unlikely to undertake significant R&D initiatives in the near future. Selvaraju reiterates a Buy rating on the shares.
PSDV pSivida

05/30/17
RODM
05/30/17
INITIATION
Target $8
RODM
Buy
pSivida initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Raghuram Selvaraju started pSivida with a Buy rating and $8 price target.
06/13/17
LTCO
06/13/17
NO CHANGE
Target $12.5
LTCO
Buy
pSivida data on Durasert provide basis for NDA filing, says Ladenburg
Ladenburg analyst Matthew Kaplan was "impressed" with the results from pSivida's second Phase 3 trial of Durasert, which he said strongly confirm the efficacy and safety seen in the earlier study and can serve as the basis for a U.S. NDA filing. The company currently plans an NDA filing by Q4 and plans to commercialize Durasert via a contract sales organization, noted Kaplan, who reiterates a Buy rating and $12.50 price target on the stock, which is down 32c, or 15%, to $1.76 in afternoon trading.
LPCN Lipocine

02/21/17
ROTH
02/21/17
NO CHANGE
Target $38
ROTH
Buy
Lipocine price target raised to $38 from $30 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Lipocine to $38 from $30 following clarity on LPCN-1107's pivotal trial design. The analyst reiterates a Buy rating on the shares.
12/20/16
ADAM
12/20/16
INITIATION
Target $15
ADAM
Buy
Lipocine assumed with a Buy at Canaccord
Canaccord analyst Dewey Steadman assumed Lipocine with Buy and $15 price target citing its status as one of the leading companies developing oral testosterone replacement therapies to treat hypogonadism.
06/20/17
ADAM
06/20/17
NO CHANGE
Target $11
ADAM
Buy
Lipocine data sets path toward FDA submission, says Canaccord
Canaccord analyst Dewey Steadman noted Lipocine reported positive top-line data for its dosing validation and dosing flexibility studies, which were required for the resubmission of its oral testosterone NDA. The analyst sees a resubmission in Q3 and believes the company has sufficient capital to meet near-term needs while the company plans to partner the drug. Steadman reiterated his Buy rating and raised his price target to $11 from $10 on Lipocine shares.
10/11/16
ADAM
10/11/16
NO CHANGE
Target $15
ADAM
Buy
Lipocine price target raised to $15 from $6 at Canaccord
Canaccord analyst John Newman raised his price target on Lipocine to $15 from $6 as he believes its oral testosterone product has better safety and convenience versus currently marketed gels and injectables. The analyst sees rapid market share gains and a 20% market share by 2024. Newman reiterated his Buy rating on Lipocine shares.
ARDM Aradigm
$3.36

0.83 (32.81%)

12/01/16
LTCO
12/01/16
NO CHANGE
Target $7.5
LTCO
Buy
Aradigm price target lowered to $7.50 from $26 at Ladenburg
Ladenburg analyst Matthew Kaplan said he continues to believe Pulmaquin is an approvable drug despite the fact that Aradigm's ORBIT 4 study achieved its primary endpoint but the ORBIT 3 study failed to achieve statistical significance on the primary TTF-PE endpoint. Based on the uncertainty for the path forward for the Pulmaquin program after the mixed ORBIT results, Kaplan lowered his price target on the stock to $7.50 from $26, though he keeps a Buy rating on Aradigm shares.
ARNA Arena Pharmaceuticals
$25.75

0.66 (2.63%)

06/27/17
06/27/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. JPMorgan analyst Alex Yao resumed coverage of Alibaba (BABA) Group with an Overweight rating and $190 price target following a period of restriction. The rating is unchanged and the price target is raised from $140. 2. SunTrust analyst Terry Tillman initiated Salesforce (CRM) with a Buy and a $110 price target and views its as a core holding for large-cap investors. 3. Citi analyst Joel Beatty started Arena Pharmaceuticals (ARNA) with a Buy rating and $23 price target. 4. Deutsche Bank analyst Bryan Kraft started Lionsgate Class A (LGF.A) shares with a Hold rating and $29 price target. 5. Cantor Fitzgerald analyst Louise Chen assumed coverage of Amarin (AMRN) with an Overweight rating and $10 price target. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/11/17
SBSH
07/11/17
NO CHANGE
Target $37
SBSH
Buy
Arena Pharmaceuticals price target raised to $37 from $23 at Citi
07/11/17
JMPS
07/11/17
NO CHANGE
JMPS
Arena Pharmaceuticals price target raised to $36 from $27 at JMP Securities
JMP Securities analyst Jason Butler says that the Phase 2 results of Arena's Ralinepag in PAH indicates that it has "a compelling clinical profile" that supports "a blockbuster commercial opportunity." The analyst adds that the drug can become "the best-in-class oral prostacyclin receptor agonist." He raised his price target on the shares to $36 from $27 and keeps an Outperform rating on the stock.
07/11/17
LEER
07/11/17
NO CHANGE
Target $53
LEER
Outperform
Arena Pharmaceuticals price target raised to $53 from $47 at Leerink
Leerink analyst Joseph Schwartz raised his price target for Arena Pharmaceuticals to $53 from $47 after the company reported "promising" topline results from its Phase 2 ralinepag study in pulmonary arterial hypertension that surpassed the benchmark established by its competitor selexipag. On the heels of ralinepag data, the analyst believes investors will begin to assign greater value to the company's proprietary pipeline that could present further upside in not only mass-market indications like ulcerative colitis and pain, but also in the rare manifestations including pyoderma gangrenosum and extraintestinal manifestations. Schwartz reiterates an Outperform rating on the shares.
BDSI BioDelivery Sciences

08/14/17
08/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Brighthouse Financial (BHF) initiated with an Equal Weight at Morgan Stanley. 2. Kala Pharmaceuticals (KALA) was initiated with a Buy at BofA/Merrill, an Outperform at Wedbush, Wells Fargo, and Wedbush, as well as an Overweight at JPMorgan. 3. BioDelivery Sciences (BDSI) coverage assumed with an Overweight at Cantor. 4. Calyxt (CLXT) was initiated with an Outperform at Wells Fargo and a Buy at Jefferies. 5. TPG RE Finance (TRTX) was initiated with a Buy at BofA/Merrill, and a Neutral at JPMorgan and Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
08/14/17
CANT
08/14/17
INITIATION
CANT
Overweight
BioDelivery Sciences coverage assumed with an Overweight at Cantor
Cantor analyst Brandon Folkes assumed coverage of BioDelivery Sciences with a $4.50 price target and an Overweight rating. The analyst thinks that two of the company's products could be boosted by the FDA's efforts to promote the use of pain treatments that are less likely than opioids to be abused and become addictive .
06/09/17
HCWC
06/09/17
NO CHANGE
Target $4
HCWC
Buy
Wainwright positive on BioDelivery Sciences after FDA action on Opana
H.C. Wainwright analyst Corey Davis is more confident in BioDelivery Sciences' (BDSI) ability to grow Belbuca after the FDA requested that Endo (ENDP) remove tamper resistant Opana ER from the market due to abuse-related public health concerns. The market, with the help of regulators, will move toward inherently less abused and safer alternatives, Davis tells investors in a research note. He believes BioDelivery's Belbuca is well positioned in the market to address that need. The analyst is more confident that Belbuca can grow from the current $23M run-rate towards his greater than $120M 2023 estimate. Davis keeps a Buy rating on the shares with a $4 price target.
AVXL Anavex
$4.01

-0.12 (-2.91%)

11/28/16
MAXM
11/28/16
NO CHANGE
Target $15
MAXM
Buy
Anavex may be targeting 'ideal approach' to Alzheimer's disease, says Maxim
After Eli Lilly's (LLY) solanezumab failed its third Phase 3 study in early-stage Alzheimer's disease, Maxim analyst Jason McCarthy noted that Anavex's (AVXL) 2-73 targets the disease "more broadly upstream" to restore proper CNS cell function and has shown "promising early data." While too soon to draw any firm conclusions, given the lessons learned from failures in pursuit of other avenues, Anavex "may be on the right track" by looking upstream, said McCarthy, who keeps a Buy rating and $15 price target on the stock.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Anavex initiated with a Buy at Noble Financial
Noble Financial analyst Kumaraguru Raja initiated Anavex with a Buy and a $16 price target. The lead product candidate, ANAVEX 2-73, is on path for a Phase 2/3 in Alzheimer's disease and a Phase 2 study in Rett's Syndrome. In previous trials, ANAVEX 2-73 has exhibited a high affinity and selection to sigma-1 receptors, and has shown synergistic action with other receptors, such as Muscarinic and N-methyl-D-aspartate in clinical trials. The drug has also displayed a favorable side effect profile, which can be beneficial to patients and advantageous when compared to current treatments. Anavex has received a grant from the International Rett Syndrome Foundation for at least $600,000, based on promising animal data. This grant is expected to cover most of the cost of the planned Phase 2 clinical trial of ANAVEX 2-73 in Rett syndrome.
02/07/17
NBLE
02/07/17
INITIATION
Target $16
NBLE
Buy
Anavex initiated with a Buy at Noble Financial
Noble Financial initiated Anavex with a Buy and a $16 price target.
OFIX Orthofix
$47.66

-0.19 (-0.40%)

06/14/17
LTCO
06/14/17
INITIATION
Target $53.25
LTCO
Buy
Orthofix initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Jeffrey Cohen started Orthofix with a Buy rating and $53.25 price target.
05/23/17
RHCO
05/23/17
INITIATION
RHCO
Buy
Orthofix initiated with a Buy at SunTrust
SuinTrust analyst Bruce Nudell started coverage of Orthofix with a $49 price target and a Buy rating. The analyst says that the company has improved its "operational efficiency" and can use M&a to accelerate its growth and boost its stock multiple. He thinks the company will generate "modest" organic growth and steady margins going forward, excluding any M&A.
06/20/17
BTIG
06/20/17
INITIATION
Target $52
BTIG
Buy
Orthofix initiated with a Buy at BTIG
BTIG analyst Ryan Zimmerman started Orthofix with a Buy rating and $52 price target, saying its strong gross margins and sizable EBITDA should result in strong free cash flow.
VNRX VolitionRx
$2.88

-0.1 (-3.36%)

TODAY'S FREE FLY STORIES

MSBI

Midland States

$33.03

-0.07 (-0.21%)

19:02
10/16/17
10/16
19:02
10/16/17
19:02
Hot Stocks
Midland States to acquire Alpine Bancorporation in roughly $181M deal »

Midland States Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 15

    Nov

MYL

Mylan

$38.18

0.23 (0.61%)

, AGN

Allergan

$198.41

-7.11 (-3.46%)

18:46
10/16/17
10/16
18:46
10/16/17
18:46
Hot Stocks
Mylan CEO: 'Pleased' with court ruling on Allergan's Restasis patents »

Mylan (MYL) announced…

MYL

Mylan

$38.18

0.23 (0.61%)

AGN

Allergan

$198.41

-7.11 (-3.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 20

    Oct

  • 23

    Oct

  • 01

    Nov

  • 06

    Nov

  • 03

    Dec

NFLX

Netflix

$202.68

3.19 (1.60%)

18:44
10/16/17
10/16
18:44
10/16/17
18:44
Hot Stocks
Netflix says seeing steady growth, great success for streaming »

Says still has bias…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 22

    Oct

PCG

PG&E

$53.43

-4.29 (-7.43%)

18:42
10/16/17
10/16
18:42
10/16/17
18:42
Hot Stocks
PG&E sees restoring service to all electric customers in CA affected by fires »

PG&E said that more…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

  • 05

    Nov

  • 05

    Nov

CYTR

CytRx

$0.38

-0.0142 (-3.64%)

18:29
10/16/17
10/16
18:29
10/16/17
18:29
Hot Stocks
CytRx granted listing extension pending results of stockholder vote »

CytRx 's request for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

EADSY

Airbus

$22.75

-0.07 (-0.31%)

, BDRBF

Bombardier

$1.88

0.03 (1.62%)

18:27
10/16/17
10/16
18:27
10/16/17
18:27
Hot Stocks
Airbus and Bombardier announce C Series partnership »

Airbus (EADSY) and…

EADSY

Airbus

$22.75

-0.07 (-0.31%)

BDRBF

Bombardier

$1.88

0.03 (1.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

18:16
10/16/17
10/16
18:16
10/16/17
18:16
Conference/Events
Immune Design to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 08

    Nov

PG

Procter & Gamble

$93.14

0.1 (0.11%)

18:15
10/16/17
10/16
18:15
10/16/17
18:15
Hot Stocks
Trian: P&G board election results 'too close to call' »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

AMZN

Amazon.com

$1,006.34

3.4 (0.34%)

18:14
10/16/17
10/16
18:14
10/16/17
18:14
Periodicals
NJ leaders offer up to $7B in tax incentives to lure Amazon to Newark, WSJ says »

New Jersey Governor Chris…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 22

    Oct

  • 26

    Oct

BDRBF

Bombardier

$1.88

0.03 (1.62%)

, EADSY

Airbus

$22.75

-0.07 (-0.31%)

18:09
10/16/17
10/16
18:09
10/16/17
18:09
Periodicals
Bombardier in talks with Airbus over CSeries jet unit JV, WSJ reports »

Bombardier (BDRBF) is in…

BDRBF

Bombardier

$1.88

0.03 (1.62%)

EADSY

Airbus

$22.75

-0.07 (-0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:55
10/16/17
10/16
17:55
10/16/17
17:55
Hot Stocks
Impax jumps 6% in after-hours after WSJ says Amneal deal near »

Shares of Impax are up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

IPXL

Impax

$19.95

-0.85 (-4.09%)

17:51
10/16/17
10/16
17:51
10/16/17
17:51
Periodicals
Impax and Amneal close to merger pact, WSJ says »

Impax Laboratories and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

AGII

Argo Group

$62.90

-0.25 (-0.40%)

17:36
10/16/17
10/16
17:36
10/16/17
17:36
Hot Stocks
Argo Group provides preliminary Q3 loss estimate »

Argo Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$53.65

-0.25 (-0.46%)

17:34
10/16/17
10/16
17:34
10/16/17
17:34
Earnings
First Defiance Financial reports Q3 EPS 92c, consensus 89c »

Reports Q3 NII $ $25.0M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

BRO

Brown & Brown

$48.97

-0.42 (-0.85%)

17:33
10/16/17
10/16
17:33
10/16/17
17:33
Earnings
Brown & Brown reports Q3 EPS 53c, consensus 50c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

ORIG

Ocean Rig UDW

$26.18

0.51 (1.99%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
Ocean Rig holder BlueMountain intends to recommend company hire advisers »

Ocean Rig UDW holder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NFLX

Netflix

$202.68

3.19 (1.60%)

, IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

17:31
10/16/17
10/16
17:31
10/16/17
17:31
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

NFLX

Netflix

$202.68

3.19 (1.60%)

IMDZ

Immune Design

$10.10

-0.85 (-7.76%)

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

UNH

UnitedHealth

$193.20

0.68 (0.35%)

BMI

Badger Meter

$50.80

-0.6 (-1.17%)

SONC

Sonic

$24.80

0.42 (1.72%)

ABEO

Abeona Therapeutics

$16.70

0.6 (3.73%)

VICL

Vical

$2.86

0.04 (1.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 17

    Oct

  • 17

    Oct

  • 17

    Oct

  • 22

    Oct

  • 23

    Oct

  • 08

    Nov

  • 17

    Oct

FDC

First Data

$18.01

0.39 (2.21%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Hot Stocks
First Data CAO sells 3,996 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 30

    Oct

ROSG

Rosetta Genomics

$1.00

-0.0479 (-4.57%)

17:28
10/16/17
10/16
17:28
10/16/17
17:28
Syndicate
Breaking Syndicate news story on Rosetta Genomics »

Rosetta Genomics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRS

Harris

$135.90

-0.66 (-0.48%)

17:27
10/16/17
10/16
17:27
10/16/17
17:27
Hot Stocks
Harris awarded $100M government contract modification »

Harris Corp., Clifton,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$259.75

-0.99 (-0.38%)

17:26
10/16/17
10/16
17:26
10/16/17
17:26
Hot Stocks
Boeing awarded $240.2M government contract »

The Boeing Co., Oklahoma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

PI

Impinj

$34.98

-0.71 (-1.99%)

17:22
10/16/17
10/16
17:22
10/16/17
17:22
Hot Stocks
Impinj COO sells 7,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 14

    Nov

  • 15

    Nov

ADOM

Adomani

$6.50

-0.36 (-5.25%)

17:21
10/16/17
10/16
17:21
10/16/17
17:21
Syndicate
Breaking Syndicate news story on Adomani »

Adomani files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAVE

Spirit Airlines

$33.47

-0.33 (-0.98%)

17:20
10/16/17
10/16
17:20
10/16/17
17:20
Hot Stocks
Spirit Airlines raises Q3 total RASM view to (6.5%) from (8.5%)-(7%) »

Sees Q3 ASMs up 18%. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RESN

Resonant

$4.38

-0.08 (-1.79%)

17:16
10/16/17
10/16
17:16
10/16/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Resonant »

Longboard raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.